...
首页> 外文期刊>Microbiologia Medica >Valutazione in vitro dell’associazione di glicopeptidi, ceftazidime e azitromicina nei confronti di Pseudomonas aeruginosa
【24h】

Valutazione in vitro dell’associazione di glicopeptidi, ceftazidime e azitromicina nei confronti di Pseudomonas aeruginosa

机译:糖肽,头孢他啶和阿奇霉素抗铜绿假单胞菌的体外评价

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objectives: Pseudomonas aeruginosa is an opportunistic human pathogen which is intrinsically resistant to many antibiotics and easily develops resistance towards many currently available agents. Intrisic resistance can be attributed to the low permeability of the P. aeruginosa outer membrane to a variety of antibiotics, including glycopeptides (GLYs). These drugs are active against Gram-positive bacteria and resistance is very rare, it appeared of some interest to evaluate the effect of combining these antimicrobial agents with antibiotics that might disorganize the structure of the outer membrane allowing the entry of glycopeptides into the Gram-negative cells. In order to verify this hypothesis, ceftazidime (CAZ) has been tested in association with vancomycin (VAN) or teicoplanin (TEI). The same experiments have been carried out also in the presence of azithromycin (AZI), which has been shown to interfere with some cellular synthesis in P. aeruginosa. Methods: A bacterial suspension of about 109CFU/ml was seeded on plates containing a fixed concentration of GLYs (500 mg/l) and increasing doses (2x,4x,8x,16x) of CAZ. Survivors were counted after 48 hs at 37°C. Results were interpreted as synergism (99%), additivity (90%), and indifference (10%) of the CFU/ml reduction found in the drugs combination in comparison to the drug alone. The same experiments have been repeated adding AZI (16 mg/l) and using GLYs at concentrations ranging from 500 to 300 mg/l. Results: CAZ in combination with GLYs reacted synergically in 20 out of 59 cases, additivity was found in 31/59 interactions and indifference was noted in 8/59 tests. Preliminary results (12 tests performed) indicated that the addition of AZI increased the incidence of synergisms and additivities even when using GLYs concentration of 300 mg/l (figure I). Conclusions: CAZ combined with GLYs gave additive or synergistic results in the geat majority of experiments, while the simultaneous combination of AZI, CAZ and a GLY increased the incidence of additive or synergistic effect against P. aeruginosa.These data, given the high concentration of GLYs employed, could be of particular interest in clinical situations where the drugs could be topically administered.
机译:目的:铜绿假单胞菌是一种机会性人类病原体,对多种抗生素具有内在抗性,并容易对许多目前可用的药物产生抗性。内源性抗性归因于铜绿假单胞菌外膜对多种抗生素(包括糖肽(GLYs))的低渗透性。这些药物对革兰氏阳性细菌具有活性,耐药性非常罕见,评估将这些抗微生物剂与抗生素结合使用可能会破坏外膜结构,使糖肽进入革兰氏阴性菌的作用似乎引起了人们的兴趣。细胞。为了验证这一假设,已与万古霉素(VAN)或替考拉宁(TEI)联合测试了头孢他啶(CAZ)。在存在阿奇霉素(AZI)的情况下也进行了相同的实验,已证明该试剂会干扰铜绿假单胞菌的某些细胞合成。方法:将约109CFU / ml的细菌悬浮液接种在含有固定浓度的GLYs(500 mg / l)和增加剂量(2x,4x,8x,16x)的CAZ板上。在37°C下48小时后对幸存者进行计数。结果被解释为与单独的药物相比,在药物组合中发现的CFU / ml降低具有协同作用(99%),可加性(90%)和无差异(10%)。添加AZI(16 mg / l)并使用500至300 mg / l浓度的GLYs,重复了相同的实验。结果:59例病例中有20例CAZ与GLYs协同反应,在31/59相互作用中发现可加性,在8/59试验中发现无差异。初步结果(进行了12个测试)表明,即使使用300 mg / l的GLYs,添加AZI也会增加协同作用和可加性的发生率(图I)。结论:CAZ与GLYs结合在大多数实验中获得了累加或协同的结果,而AZI,CAZ和GLY的同时结合增加了对铜绿假单胞菌的累加或协同作用的发生率。在可以局部施用药物的临床情况下,所使用的GLYs可能特别有意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号